Modified release formulations and methods of treating inflammatory bowel disease

• US 20060223787A1
• Filed: 03/10/2006
• Published: 10/05/2006
• Est. Priority Date: 09/03/2003
• Status: Active Grant

• Current Assignee: Allergan Pharmaceuticals International Ltd. (Abbvie Incorporated)
• Original Assignee: AGI Therapeutics Ltd.
• Inventors: Butler, Jackie, Devane, John
• Granted Patent: US 7,825,106 B2
• Time in Patent Office: Days
• US Class Current: 514/159
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 31/606 having amino groups
• CPC Class Codes: A61K 31/655 Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 245/08 with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
• CPC Class Codes: C07C 251/84 having doubly-bound carbon atoms of hydrazone groups being part of rings other than six-membered aromatic rings

Abstract

Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn'"'"'s disease and ulcerative colitis.

Claims

1. A pharmaceutical composition for administration to a subject in need thereof comprising a dose of an aminosalicylate active agent chosen from 4-amino salicylic acid, 5-amino salicylic acid, and pharmaceutically acceptable salts, esters and pro-drugs thereof, and at least one pharmaceutically acceptable excipient, wherein the composition exhibits:

(a) a drug-release profile that is independent of surrounding pH and

(b) a dissolution profile, when tested in a U.S.P. Type II apparatus (paddles) at 37°

C. and 50 rpm, in pH 6.8 buffer for the test;

1 hour;

less than or equal to about 20% drug released;

2 hours;

less than or equal to about 35% drug released;

3 hours;

less than or equal to about 50% drug released;

4 hours;

less than or equal to about 60% drug released;

6 hours;

less than or equal to about 75% drug released; and

12 hours;

from about 25% to about 100% drug released; and

wherein upon administration, the composition exhibits;

(c) at least one ratio chosen from a total urine recovery or total plasma (AUC) ratio of metabolite of the active agent to the active agent greater than or equal to 10;

1, and a Cmax ratio of metabolite of the active agent to the active agent greater than or equal to 5;

1; and

(d) from greater than 30% to about 100% of the dose of the active agent excreted in the urine as metabolite of the active agent and the active agent.

2. The composition according to claim 1, wherein the dissolution profile, when tested in a U.S.P. Type II apparatus (paddles) at 37°

C. and 50 rpm, in pH 6.8 buffer for the test;

1 hour;

less than or equal to about 10% drug released;

2 hours;

less than or equal to about 20% drug released;

3 hours;

less than or equal to about 30% drug released;

4 hours;

less than or equal to about 40% drug released;

6 hours;

less than or equal to about 50% drug released; and

12 hours;

from about 25% to about 100% drug released.

3. The composition according to claim 1, wherein the dissolution profile, when tested in a U.S.P. Type II apparatus (paddles) at 37°

C. and 50 rpm, in pH 6.8 buffer for the test;

1 hour;

less than or equal to about 5% drug released;

2 hours;

less than or equal to about 10% drug released;

3 hours;

from about 5% to about 30% drug released;

4 hours;

from about 10% to about 40% drug released;

6 hours;

from about 20% to about 50% drug released; and

12 hours;

from about 40% to about 100% drug released.

4. The composition according to claim 1, wherein the composition comprises an instant-release core and a semi-permeable membrane.

5. The composition according to claim 1, wherein the composition comprises a modified-release matrix core and a semi-permeable membrane.

6. The composition according to claim 1, wherein the aminosalicylate and/or salicylic acid is 4-aminosalicylic acid or pharmaceutical salt thereof.

7. The composition according to claim 6, wherein 4-aminosalicylic acid is sodium 4-aminosalicylate.

8. The composition according to claim 1, wherein the aminosalicylate active agent is chosen from olsalazine(5,5′

-azo-bis salicylic acid), balsalazide, 4,5′

-azo-bis salicylic acid, 4,4′

-azo-bis salicylic acid, and pharmaceutically acceptable salts thereof.

9. The composition according to claim 1, wherein the at least one pharmaceutically acceptable excipient is chosen from carriers, fillers, extenders, binders, humectants, disintegrating agents, solution-retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, stabilizers, coloring agents, buffering agents, dispersing agents, preservatives, organic acids, and organic bases.

10. The composition according to claim 1, wherein the total urine recovery ratio of the metabolite of the active agent to the active agent is greater than 20:

1.

11. The composition according to claim 10, wherein the total urine recovery ratio of the metabolite of the active agent to the active agent is greater than 100:

1.

12. The composition according to claim 1, wherein the Cmax ratio of the metabolite of the active agent to the active agent is greater than or equal to 10:

1.

13. The composition according to claim 1, wherein the dose of the amiosalicylate active agent ranges from 100 mg to 8000 mg.

14. The composition according to claim 1, wherein the dose is chosen from single and divided dosages.

15. A method of treating inflammatory bowel disease comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a dose of an aminosalicylate active agent chosen from 4-amino salicylic acid, 5-amino salicylic acid, and pharmaceutically acceptable salts, esters and pro-drugs thereof, and at least one pharmaceutically acceptable excipient, wherein the composition exhibits:

(a) a drug-release profile that is independent of surrounding pH and

(b) a dissolution profile, when tested in a U.S.P. Type II apparatus (paddles) at 37°

C. and 50 rpm, in pH 6.8 buffer for the test;

1 hour;

less than or equal to about 20% drug released;

2 hours;

less than or equal to about 35% drug released;

3 hours;

less than or equal to about 50% drug released;

4 hours;

less than or equal to about 60% drug released;

6 hours;

less than or equal to about 75% drug released; and

12 hours;

from about 25% to about 100% drug released; and

wherein upon administration, the composition exhibits;

(c) at least one ratio chosen from a total urine recovery or total plasma (AUC) ratio of metabolite of the active agent to the active agent greater than or equal to 10;

1, and a Cmax ratio of metabolite of the active agent to the active agent greater than or equal to 5;

1; and

(d) from greater than 30% to about 100% of the dose of the active agent excreted in the urine as metabolite of the active agent and the active agent.

16. The method according to claim 15, wherein the pharmaceutical composition is administered in a modified-release formulation.

17. The method according to claim 15, wherein the modified-release formulation exhibits a release profile with properties chosen from delayed-release and extended-release.

18. The method according to claim 15, wherein the dose of the amiosalicylate active agent ranges from 100 mg to 8000 mg.

19. The method according to claim 15, wherein the dose is chosen from single and divided dosages.